PMID- 38415803
OWN - NLM
STAT- Publisher
LR  - 20240228
IS  - 1532-4311 (Electronic)
IS  - 0882-0139 (Linking)
DP  - 2024 Feb 28
TI  - Mogroside Ⅴ Inhibits M1 Polarization and Inflammation of Diabetic Mouse 
      Macrophages via p38 MAPK/NF-Kappab Signaling Pathway.
PG  - 1-18
LID - 10.1080/08820139.2024.2321353 [doi]
AB  - BACKGROUND: Mogroside V (MV) has anti-inflammatory properties. However, its 
      impact on macrophage polarization under diabetic condition is yet unclear. This 
      study aimed to investigate effects and underlying mechanisms of MV on 
      inflammatory response and M1 polarization of bone marrow-derived macrophages 
      (BMDMs) from diabetic mice. METHODS: BMDMs were isolated from normal and diabetic 
      C57BL/6 mice. LPS and IFN-gammawere used to produce M1-polarized BMDMs. MV treatment 
      was administered throughout the M1 polarization process with or without SB203580 
      or PDTC. Surface markers CD11b, F4/80 and CD86 of macrophages were identified 
      using flow cytometry or immunofluorescence staining. Inflammatory cytokines IL-1beta 
      and IL-6 and phosphorylation levels of p65 and p38 were examined by western blot. 
      RESULTS: High glucose increased proportion of CD11b(+)F4/80(+)CD86(+) cells, 
      protein levels of inflammatory cytokines IL-1beta and IL-6 and phosphorylation 
      levels of p65 and p38 in LPS+IFN-gamma-induced BMDMs, while they were decreased upon 
      MV treatment. Additionally, these effects were further downregulated when MV was 
      co-added with SB203580 or PDTC. CONCLUSIONS: MV suppressed M1 macrophage 
      polarization and inflammatory response, which was partially through NF-kappaB and p38 
      MAPK in LPS+IFN-gamma induced BMDMs under high glucose condition, implying the 
      potential of MV in treatment for inflammatory complications of diabetes.
FAU - Dong, Xiaoyi
AU  - Dong X
AD  - Department of Prosthodontics, College & Affiliated Hospital of Stomatology, 
      Guangxi Medical University, Nanning, Guangxi, China.
AD  - Guangxi Key Laboratory of Oral and Maxillofacial Restoration and Reconstruction, 
      Guangxi Medical University, Nanning, Guangxi, China.
FAU - Ye, Zhimao
AU  - Ye Z
AD  - Department of Prosthodontics, College & Affiliated Hospital of Stomatology, 
      Guangxi Medical University, Nanning, Guangxi, China.
AD  - Guangxi Key Laboratory of Oral and Maxillofacial Restoration and Reconstruction, 
      Guangxi Medical University, Nanning, Guangxi, China.
FAU - Li, Cuiping
AU  - Li C
AD  - Department of Prosthodontics, College & Affiliated Hospital of Stomatology, 
      Guangxi Medical University, Nanning, Guangxi, China.
AD  - Guangxi Key Laboratory of Oral and Maxillofacial Restoration and Reconstruction, 
      Guangxi Medical University, Nanning, Guangxi, China.
FAU - Li, Kongmei
AU  - Li K
AD  - Department of Prosthodontics, College & Affiliated Hospital of Stomatology, 
      Guangxi Medical University, Nanning, Guangxi, China.
AD  - Guangxi Key Laboratory of Oral and Maxillofacial Restoration and Reconstruction, 
      Guangxi Medical University, Nanning, Guangxi, China.
FAU - Zhong, Xiaoxia
AU  - Zhong X
AD  - Department of Prosthodontics, College & Affiliated Hospital of Stomatology, 
      Guangxi Medical University, Nanning, Guangxi, China.
AD  - Guangxi Key Laboratory of Oral and Maxillofacial Restoration and Reconstruction, 
      Guangxi Medical University, Nanning, Guangxi, China.
FAU - Li, Hao
AU  - Li H
AD  - Department of Prosthodontics, College & Affiliated Hospital of Stomatology, 
      Guangxi Medical University, Nanning, Guangxi, China.
AD  - Guangxi Key Laboratory of Oral and Maxillofacial Restoration and Reconstruction, 
      Guangxi Medical University, Nanning, Guangxi, China.
LA  - eng
PT  - Journal Article
DEP - 20240228
PL  - England
TA  - Immunol Invest
JT  - Immunological investigations
JID - 8504629
SB  - IM
OTO - NOTNLM
OT  - Bone marrow-derived macrophages
OT  - NF-kappaB
OT  - high glucose
OT  - macrophage polarization
OT  - mogroside V
OT  - p38 MAPK
EDAT- 2024/02/28 12:42
MHDA- 2024/02/28 12:42
CRDT- 2024/02/28 09:39
PHST- 2024/02/28 12:42 [medline]
PHST- 2024/02/28 12:42 [pubmed]
PHST- 2024/02/28 09:39 [entrez]
AID - 10.1080/08820139.2024.2321353 [doi]
PST - aheadofprint
SO  - Immunol Invest. 2024 Feb 28:1-18. doi: 10.1080/08820139.2024.2321353.